Health Care Related Organization
Transcarent Acquires Accolade for $621 Million in Strategic Healthcare Deal
Transcarent, Accolade, healthcare acquisition, personalized healthcare, AI-powered healthcare, healthcare technology
FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines
RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy
Fierce Health Payer Summit 2025: Shaping the Future of Healthcare Payers
Fierce Health Payer Summit, healthcare payers, value-based care, behavioral health, payer-provider alignment, healthcare industry trends.
Sanofi Partners with Alloy Therapeutics in $400M Deal to Advance Antisense Therapeutics
Sanofi, Alloy Therapeutics, Antisense Therapeutics, Biobucks Deal, Genetic Medicine
Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)
AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.
Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform
Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine
J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial
J&J, Rybrevant, AstraZeneca, Tagrisso, lung cancer, NSCLC, survival trial, combination therapy
Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter
Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel
I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space
I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development
2024 FDA Drug Approvals: Small Companies Make Significant Impact
FDA drug approvals 2024, small biotech companies, pharmaceutical industry, new drug approvals, regulatory updates.